CN105250520A - Drug composition for treating cataract - Google Patents
Drug composition for treating cataract Download PDFInfo
- Publication number
- CN105250520A CN105250520A CN201510693302.6A CN201510693302A CN105250520A CN 105250520 A CN105250520 A CN 105250520A CN 201510693302 A CN201510693302 A CN 201510693302A CN 105250520 A CN105250520 A CN 105250520A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- treatment
- cataract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of cataract treatment and especially relates to a drug composition for treating cataract. The drug composition is prepared from, by weight, 15-20 parts of codonopsis pilosula, 15-20 parts of astragalus roots, 8-13 parts of ganoderma lucidum, 20-25 parts of wolfberries, 10-15 parts of butterflybush flowers, 10-15 parts of hedge prinsepia nut pulp, 10-13 parts of selfheal, 8-12 parts of chrysanthemun flower, 5-8 parts of coptis chinensis, 10-15 parts of radix scutellariae, 10-15 parts of honeysuckle stems, 20-25 parts of dandelion, 8-13 parts of glossy privet fruits, 12-15 parts of red-rooted salvia roots, 10-13 parts of white atractylodes rhizomes and 10-15 parts of bat dung and 10-15 parts of violet herb. Compared with the prior art, the drug composition for treating the cataract has the advantages of promoting multi-aspect regulation of the liver, kidney and spleen, further improving the treatment effect, avoiding additional acupuncture treatment and bringing great convenience to patients to take the medical treatment.
Description
Technical field
The present invention relates to the cataractous technical field for the treatment of, particularly one treats cataractous pharmaceutical composition.
Background technology
Cataractous cardinal symptom is visual disorder, and it is relevant with position with lenticular opacities degree.Serious cataract can blinding.Modern Chinese medicine treatment cataract, the earliest be reported in nineteen fifty-seven.Over more than 40 year, treat on the basis of cataracta ophthalmopathy ancient times in succession, the aspect such as pathogenesis, the rule for the treatment of, method for the treatment of of the traditional Chinese medical science to primary disease develops all to some extent.
Many ophthalmologist oculists emphasize, primary disease is in the majority with deficiency syndrome, dirty relevant with liver,kidney,spleen three, wherein close with the hepatic and renal YIN deficiency, even someone the person proposed cloudy gas only for audiovisual in 30 years, then can there is the viewpoint from cataract in deficiency of the liver and kindey after 30 years.When treating cataract, someone uses herbal treatment, and existing taste of Chinese medicine number mismate, have impact on pharmic function plays, and then reduces therapeutical effect, causes curative effect undesirable.In method for the treatment of, in order to improve therapeutic effect, also adopt acupuncture, acupuncture is to recovering vision, determined curative effect, but acupuncture comparatively bothers, just need patient to go to hospital to complete.
In order to solve the deficiency of above-mentioned Therapeutic Method, to seek medical advice angle from being convenient to patient, therefore being necessary to provide a kind for the treatment of completely newly cataractous pharmaceutical composition.
Summary of the invention
The object of the invention is to the defect for prior art and deficiency, provide a kind of patient of being convenient to seek medical advice and there is the cataractous pharmaceutical composition for the treatment of of obvious curative effects.
For achieving the above object, the technical solution used in the present invention is:
One of the present invention treats cataractous pharmaceutical composition, and described pharmaceutical composition is made up of each component of following weight proportioning,
Radix Codonopsis 15 ~ 20 parts, the Radix Astragali 15 ~ 20 parts,
Ganoderma 8 ~ 13 parts, Fructus Lycii 20 ~ 25 parts,
Flos Buddlejae 10 ~ 15 parts, Nux Prinsepiae meat 10 ~ 15 parts,
Spica Prunellae 10 ~ 13 parts, Flos Chrysanthemi 8 ~ 12 parts,
Rhizoma Coptidis 5 ~ 8 parts, Radix Scutellariae 10 ~ 15 parts,
Caulis Lonicerae 10 ~ 15 parts, Herba Taraxaci 20 ~ 25 parts,
Fructus Ligustri Lucidi 8 ~ 13 parts, Radix Salviae Miltiorrhizae 12 ~ 15 parts,
The Rhizoma Atractylodis Macrocephalae 10 ~ 13 parts, Faeces Vespertilionis 10 ~ 15 parts; Herba Violae 10 ~ 15 parts.
Further, described pharmaceutical composition is made up of each component of following weight proportioning: Radix Codonopsis is 15 parts, and the Radix Astragali is 18 parts, Ganoderma is 8 parts, and Fructus Lycii is 23 parts, and Flos Buddlejae is 10 parts, Nux Prinsepiae meat is 10 parts, and Spica Prunellae is 10 parts, and Flos Chrysanthemi is 10 parts, Rhizoma Coptidis is 5 parts, and Radix Scutellariae is 10 parts, and Caulis Lonicerae is 12 parts, Herba Taraxaci is 20 parts, and Fructus Ligustri Lucidi is 8 parts, and Radix Salviae Miltiorrhizae is 12 parts, the Rhizoma Atractylodis Macrocephalae is 13 parts, and Faeces Vespertilionis is 10 parts, Herba Violae 10 parts.
Further, described pharmaceutical composition is made up of each component of following weight proportioning, and Radix Codonopsis is 18 parts, and the Radix Astragali is 15 parts, Ganoderma is 9 parts, and Fructus Lycii is 20 parts, and Flos Buddlejae is 15 parts, Nux Prinsepiae meat is 13 parts, and Spica Prunellae is 11 parts, and Flos Chrysanthemi is 8 parts, Rhizoma Coptidis is 8 parts, and Radix Scutellariae is 13 parts, and Caulis Lonicerae is 10 parts, Herba Taraxaci is 23 parts, and Fructus Ligustri Lucidi is 11 parts, and Radix Salviae Miltiorrhizae is 15 parts, the Rhizoma Atractylodis Macrocephalae is 10 parts, and Faeces Vespertilionis is 11 parts, Herba Violae 12 parts.
Further, described pharmaceutical composition is made up of each component of following weight proportioning, and Radix Codonopsis is 20 parts, and the Radix Astragali is 20 parts, Ganoderma is 13 parts, and Fructus Lycii is 25 parts, and Flos Buddlejae is 13 parts, Nux Prinsepiae meat is 15 parts, and Spica Prunellae is 13 parts, and Flos Chrysanthemi is 12 parts, Rhizoma Coptidis is 7 parts, and Radix Scutellariae is 15 parts, and Caulis Lonicerae is 15 parts, Herba Taraxaci is 25 parts, and Fructus Ligustri Lucidi is 13 parts, and Radix Salviae Miltiorrhizae is 13 parts, the Rhizoma Atractylodis Macrocephalae is 12 parts, and Faeces Vespertilionis is 15 parts, Herba Violae 15 parts.
The present invention's beneficial effect is compared with prior art: Radix Codonopsis, the Radix Astragali, Ganoderma, Fructus Lycii, Flos Buddlejae, Nux Prinsepiae meat, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae and Faeces Vespertilionis mixing are with replenishing QI to invigorate the spleen, kidney-replenishing blood-nourishing, and barrier is moved back in lung heat clearing; Spica Prunellae promoting blood circulation and hemostasis, Flos Chrysanthemi removing toxic substances improving eyesight, Radix Scutellariae lung heat clearing intestinal heat, Rhizoma Coptidis clearing away heart-fire detoxification, Caulis Lonicerae removing toxic substances is active, Herba Taraxaci mass dissipating and swelling eliminating, Herba Violae detumescence and apocenosis, so Spica Prunellae, Flos Chrysanthemi, Radix Scutellariae, Rhizoma Coptidis, Caulis Lonicerae, Herba Taraxaci and Herba Violae mixing are with blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, detumescenceization knot, dry liver improving eyesight; Promote that liver,kidney,spleen all obtains adjustment in many ways, and then improve therapeutic effect, avoid increasing acupuncture and moxibustion therapy, be very easy to patient and seek medical advice.
Detailed description of the invention
Describe the present invention below in conjunction with specific embodiment, following embodiment and explanation are only used for explaining the present invention, but not as a limitation of the invention.
Described pharmaceutical composition is made up of each component of following weight proportioning,
Radix Codonopsis 15 ~ 20 parts, the Radix Astragali 15 ~ 20 parts,
Ganoderma 8 ~ 13 parts, Fructus Lycii 20 ~ 25 parts,
Flos Buddlejae 10 ~ 15 parts, Nux Prinsepiae meat 10 ~ 15 parts,
Spica Prunellae 10 ~ 13 parts, Flos Chrysanthemi 8 ~ 12 parts,
Rhizoma Coptidis 5 ~ 8 parts, Radix Scutellariae 10 ~ 15 parts,
Caulis Lonicerae 10 ~ 15 parts, Herba Taraxaci 20 ~ 25 parts,
Fructus Ligustri Lucidi 8 ~ 13 parts, Radix Salviae Miltiorrhizae 12 ~ 15 parts,
The Rhizoma Atractylodis Macrocephalae 10 ~ 13 parts, Faeces Vespertilionis 10 ~ 15 parts; Herba Violae 10 ~ 15 parts.
As the first example of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning: Radix Codonopsis is 15 parts, and the Radix Astragali is 18 parts, and Ganoderma is 8 parts, Fructus Lycii is 23 parts, and Flos Buddlejae is 10 parts, and Nux Prinsepiae meat is 10 parts, Spica Prunellae is 10 parts, and Flos Chrysanthemi is 10 parts, and Rhizoma Coptidis is 5 parts, Radix Scutellariae is 10 parts, and Caulis Lonicerae is 12 parts, and Herba Taraxaci is 20 parts, Fructus Ligustri Lucidi is 8 parts, and Radix Salviae Miltiorrhizae is 12 parts, and the Rhizoma Atractylodis Macrocephalae is 13 parts, Faeces Vespertilionis is 10 parts, Herba Violae 10 parts, and every part is 1g.Adopting above-mentioned prescription to decoct liquor taking, every day 2 times, each 100ml, 1 month is 1 course for the treatment of, takes 3 courses for the treatment of continuously, and in treatment Aged-related Cataract Patients 150,83 examples take an evident turn for the better, and 52 examples take a favorable turn, and 15 examples are invalid.
As the second example of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning, and Radix Codonopsis is 18 parts, and the Radix Astragali is 15 parts, Ganoderma is 9 parts, and Fructus Lycii is 20 parts, and Flos Buddlejae is 15 parts, and Nux Prinsepiae meat is 13 parts, Spica Prunellae is 11 parts, and Flos Chrysanthemi is 8 parts, and Rhizoma Coptidis is 8 parts, Radix Scutellariae is 13 parts, and Caulis Lonicerae is 10 parts, and Herba Taraxaci is 23 parts, Fructus Ligustri Lucidi is 11 parts, and Radix Salviae Miltiorrhizae is 15 parts, and the Rhizoma Atractylodis Macrocephalae is 10 parts, Faeces Vespertilionis is 11 parts, Herba Violae 12 parts, and every part is 1g.Adopting above-mentioned prescription to make oral liquid to take, every day 3 times, each 15ml, 2 months is 1 course for the treatment of, takes 3 courses for the treatment of continuously, and in treatment Aged-related Cataract Patients 100,70 examples take an evident turn for the better, and 18 examples take a favorable turn, and 12 examples are invalid.
As the 3rd example of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning, and Radix Codonopsis is 20 parts, and the Radix Astragali is 20 parts, Ganoderma is 13 parts, and Fructus Lycii is 25 parts, and Flos Buddlejae is 13 parts, and Nux Prinsepiae meat is 15 parts, Spica Prunellae is 13 parts, and Flos Chrysanthemi is 12 parts, and Rhizoma Coptidis is 7 parts, Radix Scutellariae is 15 parts, and Caulis Lonicerae is 15 parts, and Herba Taraxaci is 25 parts, Fructus Ligustri Lucidi is 13 parts, and Radix Salviae Miltiorrhizae is 13 parts, and the Rhizoma Atractylodis Macrocephalae is 12 parts, Faeces Vespertilionis is 15 parts, Herba Violae 15 parts, and every part is 1g.Adopting above-mentioned prescription to make oral liquid to take, every day 3 times, each 20ml, 40 days is 1 course for the treatment of, takes 4 courses for the treatment of continuously, and in treatment Aged-related Cataract Patients 200,137 examples take an evident turn for the better, and 46 examples take a favorable turn, and 17 examples are invalid.
Above-mentioned three kinds of examples all can decoct liquor taking, and oral liquid, the tablet that also can make Chinese medicine preparation are taken; Concrete preparation method and prior art are distinguished without matter, therefore do not speak more at this.
The present invention's beneficial effect is compared with prior art: Radix Codonopsis, the Radix Astragali, Ganoderma, Fructus Lycii, Flos Buddlejae, Nux Prinsepiae meat, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae and Faeces Vespertilionis mixing are with replenishing QI to invigorate the spleen, kidney-replenishing blood-nourishing, and barrier is moved back in lung heat clearing; Spica Prunellae promoting blood circulation and hemostasis, Flos Chrysanthemi removing toxic substances improving eyesight, Radix Scutellariae lung heat clearing intestinal heat, Rhizoma Coptidis clearing away heart-fire detoxification, Caulis Lonicerae removing toxic substances is active, Herba Taraxaci mass dissipating and swelling eliminating, Herba Violae detumescence and apocenosis, so Spica Prunellae, Flos Chrysanthemi, Radix Scutellariae, Rhizoma Coptidis, Caulis Lonicerae, Herba Taraxaci and Herba Violae mixing are with blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, detumescenceization knot, dry liver improving eyesight; Promote that liver,kidney,spleen all obtains adjustment in many ways, and then improve therapeutic effect, avoid increasing acupuncture and moxibustion therapy, be very easy to patient and seek medical advice.
The above is only in order to conveniently to illustrate the present invention, and in the scope not departing from the present invention's creation, the various simple covert and modification that the those skilled in the art being familiar with this technology does should belong to protection scope of the present invention.
Claims (4)
1. treat a cataractous pharmaceutical composition, it is characterized in that: described pharmaceutical composition is made up of each component of following weight proportioning,
Radix Codonopsis 15 ~ 20 parts, the Radix Astragali 15 ~ 20 parts,
Ganoderma 8 ~ 13 parts, Fructus Lycii 20 ~ 25 parts,
Flos Buddlejae 10 ~ 15 parts, Nux Prinsepiae meat 10 ~ 15 parts,
Spica Prunellae 10 ~ 13 parts, Flos Chrysanthemi 8 ~ 12 parts,
Rhizoma Coptidis 5 ~ 8 parts, Radix Scutellariae 10 ~ 15 parts,
Caulis Lonicerae 10 ~ 15 parts, Herba Taraxaci 20 ~ 25 parts,
Fructus Ligustri Lucidi 8 ~ 13 parts, Radix Salviae Miltiorrhizae 12 ~ 15 parts,
The Rhizoma Atractylodis Macrocephalae 10 ~ 13 parts, Faeces Vespertilionis 10 ~ 15 parts; Herba Violae 10 ~ 15 parts.
2. one according to claim 1 treats cataractous pharmaceutical composition, it is characterized in that: described pharmaceutical composition is made up of each component of following weight proportioning: Radix Codonopsis is 15 parts, and the Radix Astragali is 18 parts, Ganoderma is 8 parts, and Fructus Lycii is 23 parts, and Flos Buddlejae is 10 parts, Nux Prinsepiae meat is 10 parts, and Spica Prunellae is 10 parts, and Flos Chrysanthemi is 10 parts, Rhizoma Coptidis is 5 parts, and Radix Scutellariae is 10 parts, and Caulis Lonicerae is 12 parts, Herba Taraxaci is 20 parts, and Fructus Ligustri Lucidi is 8 parts, and Radix Salviae Miltiorrhizae is 12 parts, the Rhizoma Atractylodis Macrocephalae is 13 parts, and Faeces Vespertilionis is 10 parts; Herba Violae 10 parts.
3. one according to claim 1 treats cataractous pharmaceutical composition, it is characterized in that: described pharmaceutical composition is made up of each component of following weight proportioning, and Radix Codonopsis is 18 parts, and the Radix Astragali is 15 parts, Ganoderma is 9 parts, and Fructus Lycii is 20 parts, and Flos Buddlejae is 15 parts, Nux Prinsepiae meat is 13 parts, and Spica Prunellae is 11 parts, and Flos Chrysanthemi is 8 parts, Rhizoma Coptidis is 8 parts, and Radix Scutellariae is 13 parts, and Caulis Lonicerae is 10 parts, Herba Taraxaci is 23 parts, and Fructus Ligustri Lucidi is 11 parts, and Radix Salviae Miltiorrhizae is 15 parts, the Rhizoma Atractylodis Macrocephalae is 10 parts, and Faeces Vespertilionis is 11 parts, Herba Violae 12 parts.
4. one according to claim 1 treats cataractous pharmaceutical composition, it is characterized in that: described pharmaceutical composition is made up of each component of following weight proportioning, and Radix Codonopsis is 20 parts, and the Radix Astragali is 20 parts, Ganoderma is 13 parts, and Fructus Lycii is 25 parts, and Flos Buddlejae is 13 parts, Nux Prinsepiae meat is 15 parts, and Spica Prunellae is 13 parts, and Flos Chrysanthemi is 12 parts, Rhizoma Coptidis is 7 parts, and Radix Scutellariae is 15 parts, and Caulis Lonicerae is 15 parts, Herba Taraxaci is 25 parts, and Fructus Ligustri Lucidi is 13 parts, and Radix Salviae Miltiorrhizae is 13 parts, the Rhizoma Atractylodis Macrocephalae is 12 parts, and Faeces Vespertilionis is 15 parts, Herba Violae 15 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510693302.6A CN105250520A (en) | 2015-10-24 | 2015-10-24 | Drug composition for treating cataract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510693302.6A CN105250520A (en) | 2015-10-24 | 2015-10-24 | Drug composition for treating cataract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250520A true CN105250520A (en) | 2016-01-20 |
Family
ID=55090650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510693302.6A Pending CN105250520A (en) | 2015-10-24 | 2015-10-24 | Drug composition for treating cataract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250520A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109763A (en) * | 2016-09-05 | 2016-11-16 | 高山 | One treats cataractous Chinese medicine composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869631A (en) * | 2010-06-25 | 2010-10-27 | 王晓岚 | Toxicant elimination medicament for eyes |
| CN102670993A (en) * | 2012-05-09 | 2012-09-19 | 杨文江 | Chinese medicament for treating cataract |
| CN102949540A (en) * | 2012-11-20 | 2013-03-06 | 孙斌 | Traditional Chinese medicinal composite for treating cataract |
-
2015
- 2015-10-24 CN CN201510693302.6A patent/CN105250520A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869631A (en) * | 2010-06-25 | 2010-10-27 | 王晓岚 | Toxicant elimination medicament for eyes |
| CN102670993A (en) * | 2012-05-09 | 2012-09-19 | 杨文江 | Chinese medicament for treating cataract |
| CN102949540A (en) * | 2012-11-20 | 2013-03-06 | 孙斌 | Traditional Chinese medicinal composite for treating cataract |
Non-Patent Citations (2)
| Title |
|---|
| 中国人民解放军总后勤部卫生部 南京军区医学校: "《眼科学》", 31 December 1980, 中国人民解放军战士出版社 * |
| 施杞: "《现代中医药应用与研究大系 第十三卷 五官科》", 30 September 1998, 上海中医药大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109763A (en) * | 2016-09-05 | 2016-11-16 | 高山 | One treats cataractous Chinese medicine composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104324355A (en) | Traditional Chinese medicine composition for treating peripheral neuropathy caused by diabetes | |
| CN103736018A (en) | Medicine for treating gallstones and preparation method thereof | |
| CN103920074A (en) | Traditional Chinese medicine composition for treating hepatitis B | |
| CN101164611A (en) | Traditional Chinese medicine for treating invasion of lung by cold type pertussis | |
| CN103432330B (en) | Traditional Chinese medicine used for treating renal failure and preparation method thereof | |
| CN104587414A (en) | Traditional Chinese medicinal composition for treating headache | |
| CN105250520A (en) | Drug composition for treating cataract | |
| CN105056104A (en) | Traditional Chinese medicine for treating hepatitis | |
| CN104173818A (en) | Traditional Chinese medicine composition for treating calculus | |
| CN102327553A (en) | Traditional Chinese medicine for treating pyogenic osteomyelitis | |
| CN103191229B (en) | Traditional Chinese medicine for treating swelling of knee joints | |
| CN103432467B (en) | Traditional Chinese medicine used for treating uremia and preparation method thereof | |
| CN102631450A (en) | Traditional Chinese medicine (TCM) decoction for treating wind-cold type common cold | |
| CN101095810B (en) | Decoction medicine for treating seborrhoeic dermatitis and method for preparing the same | |
| CN104189511A (en) | Traditional Chinese medicine preparation for treating chronic cholecystitis | |
| CN110585300A (en) | Medicine for treating arthralgia-synadrome and preparation method thereof | |
| CN103385954A (en) | Traditional Chinese medicine composition used for treating kidney stones | |
| CN103330814A (en) | Traditional Chinese medicine composition for treating deficiency of kidney yang | |
| CN101940720A (en) | Traditional Chinese herbal medicine for treating peptic ulcer (blood stasis obstructing the collaterals) | |
| CN101176768A (en) | Epityphlon health | |
| CN106237139A (en) | The preparation method of the oral liquid for the treatment of acute infantile convulsion wind | |
| CN105920292A (en) | Chinese medicinal composition for treating acute mastitis | |
| CN104758455A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN105267884A (en) | Medicine for mitral valve combined aortic lesion heart disease | |
| CN104758554A (en) | Traditional Chinese medicine composition for treating headache |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160120 |